Literature DB >> 18047516

Genetics of melanoma tumorigenesis.

M Singh1, J Lin, T L Hocker, H Tsao.   

Abstract

Melanoma therapy is moving away from combinatorial approaches and towards newer targeted strategies. With the identification of mutations in various RAS pathway genes, there are now tremendous opportunities to bring inhibitors of RAS signalling to the clinical arena.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18047516     DOI： 10.1111/j.1365-2133.2007.08316.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


  15 in total

1.  Mutational status of naevus-associated melanomas.

Authors:  D Shitara; G Tell-Martí; C Badenas; M M S S Enokihara; L Alós; A B Larque; N Michalany; J A Puig-Butille; C Carrera; J Malvehy; S Puig; E Bagatin
Journal:  Br J Dermatol       Date:  2015-06-19       Impact factor: 9.302

2.  Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.

Authors:  Tatsuhiro Shibata; Akiko Kokubu; Masashi Miyamoto; Yuko Sasajima; Naoya Yamazaki
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

3.  Targeting sphingosine kinase-1 to inhibit melanoma.

Authors:  SubbaRao V Madhunapantula; Jeremy Hengst; Raghavendra Gowda; Todd E Fox; Jong K Yun; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2012-03       Impact factor: 4.693

Review 4.  Interaction of molecular alterations with immune response in melanoma.

Authors:  Robert A Szczepaniak Sloane; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; Xue Zhang; Alexandre Reuben; Jennifer A Wargo
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

5.  The Immunogenetics of Melanoma.

Authors:  Farzaneh Darbeheshti
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Authors:  Jeffrey Zhao; Carlos Galvez; Kathryn Eby Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-08-11

7.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

Review 8.  Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy.

Authors:  Sangeetha M Reddy; Alexandre Reuben; Jennifer A Wargo
Journal:  Curr Oncol Rep       Date:  2016-07       Impact factor: 5.075

9.  Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish.

Authors:  Cristina Santoriello; Elisa Gennaro; Viviana Anelli; Martin Distel; Amanda Kelly; Reinhard W Köster; Adam Hurlstone; Marina Mione
Journal:  PLoS One       Date:  2010-12-10       Impact factor: 3.240

10.  Molecular dermatopathology in malignant melanoma.

Authors:  Marie-Annick Reginster; Claudine Pierard-Franchimont; Gérald E Piérard; Pascale Quatresooz
Journal:  Dermatol Res Pract       Date:  2011-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.